Navigation Links
Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
Date:9/14/2007

DUBLIN, Ohio, Sept. 14 /PRNewswire-FirstCall/ -- In advance of its annual investor meeting, Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, reaffirmed its earnings-per-share (EPS) target for the fiscal year and updated the profit outlook for its operating segments.

The company said non-GAAP EPS from continuing operations(1) is still expected to exceed the long-term goal of 12 to 16 percent growth it set in June, finishing the year in a range of $3.95 to $4.15 per share.

To reflect an industry-wide moderation in the sale of prescription drugs, the company revised the outlook for its Supply Chain Pharmaceutical segment, which is now expected to grow profit during the year in line with its long-term goal of 7 to 10 percent growth. Cardinal Health previously said profit growth for this segment was expected at the top end of the long-term range.

Financial targets remain unchanged for the company's three other operating segments.

"While market factors led us to revise our outlook for the Supply Chain Pharma segment, the strength of our Clinical and Medical Products businesses allow us to maintain our EPS guidance range for the full year," said R. Kerry Clark, chief executive officer of Cardinal Health. "The diversity of our portfolio is a key differentiator, offering stable growth and strong cash flow in our core supply chain services sector, and faster growth with higher returns in our clinical and medical products sector."

The company will host its annual meeting for invited investment professionals and financial analysts on Sept. 19 in New York. More information about the meeting may be found on the investor page of http://www.cardinalhealth.com.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $87 billion, global company serving the health-care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems, MedMined(R) data mining software and the CareFusion(TM) patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500 and No. 1 in its sector on Fortune's ranking of Most Admired firms, Cardinal Health employs more than 40,000 on five continents. More information about the company may be found at http://www.cardinalhealth.com.

1 Non-GAAP diluted EPS from continuing operations: earnings from continuing operations, excluding special items and impairment charges and other, both net of tax, divided by diluted weighted average shares outstanding.

Non-GAAP Financial Measures

The Company presents non-GAAP earnings from continuing operations (and presentations derived from this financial measure) on a forward-looking basis. The most directly comparable forward-looking GAAP measure is earnings from continuing operations. The Company is unable to provide a quantitative reconciliation of this forward-looking non-GAAP measure to the most directly comparable forward-looking GAAP measure because the Company cannot reliably forecast special items and impairment charges and other, which are difficult to predict and estimate. Please note that the unavailable reconciling items could significantly impact the Company's future financial results.

Cautions Concerning Forward-Looking Statements

This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: competitive pressures in its various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; uncertainties relating to the timing of generic introductions and the frequency or rate of pharmaceutical price appreciation; changes in the distribution patterns or reimbursement rates for health-care products and/or services; uncertainties related to finalizing the pending settlement of the class-action securities litigation, including obtaining court approval of the settlement; successful integration of Cardinal Health and VIASYS Healthcare and the ability to achieve synergies from the acquisition; and general economic and market conditions. This news release reflects management's views as of September 14, 2007. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward- looking statement.


'/>"/>
SOURCE Cardinal Health
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Cardinal Calls For Legal Response Against Da Vinci Code
2. Poor health care in Russia maybe causing Decline in its Population
3. Startling Expose – Physicians Often Have No Regular Source Of Health Car
4. Debate Rages over firing of HIV infected health care workers
5. Want a Healthy brew? Have some Tea!
6. Patient’s perception of health status helps in better recover
7. Antioxidants protect health tissue in people undergoing radiation therapy.
8. Sexual abuse affect health for a lifetime
9. Smoking a greater risk than HIV? Yes say health experts!!!!
10. Healthcare sector is now a multi billion-dollar industry in India
11. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... VA (PRWEB) , ... June 28, 2017 , ... Guide ...      , No matter on which side of the Atlantic devicemakers do ... device regulations they have to follow. , In addition to the full text of ...
(Date:6/28/2017)... ... , ... Anyone with a remote control has seen the never-ending twists on the house flipping ... get rich in no time. But what about the buyers of the flipper's flip. ... of a flipped house. An email recently sent to Gary Case said, “Just closed ...
(Date:6/28/2017)... ... ... David B. Sosin, a founding partner at the law firm Sosin, Arnold & ... for the Illinois State Bar Association , in accordance with the organization’s rules of ... following a state-wide election and served in that capacity for the past year prior to ...
(Date:6/28/2017)... ... , ... American Farmer proudly announces the participation of Pure Line Seeds, Inc ... to broadcast fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... seed. As demand grew, the small company located in Moscow, Idaho extended its sales ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Md. , June 7, 2017  Novavax, Inc., (Nasdaq: ... second of two Phase 2 trials of its RSV F ... of child bearing age have been published in the journal ... publication have been shared in prior scientific conferences). The Company ... in April 2014. Novavax is developing the RSV F Vaccine ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: